β¨ Medicines Distribution Consents
24 JANUARY 2008 NEW ZEALAND GAZETTE, No. 9
253
Consent to the Distribution of Changed Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of
the changed medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are
set out in the Schedule hereto:
Schedule
Product:
Alimta
Active Ingredient:
Pemetrexed sodium 713mg equivalent to pemetrexed free acid 500mg
Dosage Form:
Powder for infusion
New Zealand Sponsor:
Eli Lilly and Company (NZ) Limited
Manufacturer:
Lilly France SAS, Fegersheim, France
Product:
NovoMix 30 Flexpen
Active Ingredient:
Insulin aspart 100IU/mL
Dosage Form:
Suspension for injection
New Zealand Sponsor:
Novo Nordisk Pharmaceuticals Limited
Manufacturers:
Novo Nordisk A/S, Bagsvaerd, Copenhagen, Denmark
Novo Nordisk Production S.A.S, Chartres Cedex, France
Product:
NovoMix 30 Penfill
Active Ingredient:
Insulin aspart 100IU/mL
Dosage Form:
Suspension for injection
New Zealand Sponsor:
Novo Nordisk Pharmaceuticals Limited
Manufacturers:
Novo Nordisk A/S, Bagsvaerd, Copenhagen, Denmark
Novo Nordisk Production S.A.S, Chartres Cedex, France
Dated this 18th day of January 2008.
JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation
given by the Minister of Health on 6 July 2001).
go428
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of
the new medicines set out in the Schedule hereto:
Schedule
Product:
Cervarix
Active Ingredients:
Human Papillomavirus (HPV) 16 L1 Protein 20Β΅g
Human Papillomavirus (HPV) 18 L1 Protein 20Β΅g
Dosage Form:
Suspension for injection
New Zealand Sponsor:
GlaxoSmithKline (NZ) Limited
Manufacturers:
GlaxoSmithKline Biologicals SA, Parc de la Noire Epine, Wavre, Belgium
GlaxoSmithKline Biologicals SA, Rixensart, Belgium
Product:
Emend IV
Active Ingredient:
Fosaprepitant dimeglumine 40mg/mL
Dosage Form:
Powder for injection
New Zealand Sponsor:
Merck Sharp & Dohme (New Zealand) Limited
Manufacturer:
DSM Pharmaceuticals Inc, Greenville, North Carolina, United States of America
Product:
Lamivudine
Active Ingredient:
Lamivudine 10mg/mL
Dosage Form:
Oral solution
New Zealand Sponsor:
REX Medical Limited
Manufacturer:
Cipla Limited, Salcette, Goa, India
Product:
Oxytrol
Active Ingredient:
Oxybutynin 36mg
Dosage Form:
Transdermal patch
New Zealand Sponsor:
Hospira NZ Limited
Manufacturer:
Watson Pharmaceuticals Inc., Salt Lake City, Utah, United States of America
Dated this 18th day of January 2008.\n
JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation
given by the Minister of Health on 6 July 2001).
go429
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2008, No 9
Gazette.govt.nz —
NZ Gazette 2008, No 9
β¨ LLM interpretation of page content
π₯ Consent to the Distribution of Changed Medicines
π₯ Health & Social Welfare18 January 2008
Medicines Act 1981, Changed Medicines, Distribution, Alimta, NovoMix 30 Flexpen, NovoMix 30 Penfill
- JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate
π₯ Consent to the Distribution of New Medicines
π₯ Health & Social Welfare18 January 2008
Medicines Act 1981, New Medicines, Distribution, Cervarix, Emend IV, Lamivudine, Oxytrol
- JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate